The Latest Breaking News from IDXX

IDEXX Laboratories has outpaced the Dow Jones Industrial Average this year, and analysts are reasonably upbeat about its future growth potential.

Thermo Fisher Scientific has notably underperformed the Nasdaq Composite over the past year, yet analysts remain bullish about the stock’s prospects.

Despite IDEXX Laboratories’ underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

IDEXX Laboratories is scheduled to release its fiscal third-quarter earnings this month, and analysts project a single-digit profit growth.

IDEXX Laboratories underperformed the broader healthcare sector, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

IDEXX Laboratories has underperformed the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

IDEXX Laboratories will unveil its Q2 earnings next month, and analysts anticipate a single-digit bottom-line growth.

The pet care industry’s robust expansion is driven by rising disposable income, adoption of e-commerce platforms, and rising pet ownership. Therefore, investors could consider watching fundamentally sound pet care stocks, Zoetis (ZTS), IDEXX Laboratories (IDXX), and Chewy (CHWY). Keep reading.

The healthcare industry's growth is driven by expanding healthcare needs, fast-rising demand for care services, and the increasing demand for smart medical devices. Given this backdrop, investors could consider buying fundamentally strong healthcare stocks such as IDEXX Laboratories (IDXX), Veeva Systems (VEEV), and Chemed Corporation (CHE) given their solid profitability…